Inhibition of subgenomic hepatitis C virus RNA transcription by chinese herbal extracts

References

• Alter HJ, Sanchez-Pescador R, Urdea MS, Wilber JC, Lagier RJ, Di Bisceglie AM, Shih JW, Neuwald PD (1995): Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepat 2: 121–132.
   PubMedGoogle Scholar
• Behura S, Sahoo S, Srvastava VK (2002): Major constitutents in leaf essential oils Curcuma aromatica Salisb. Cur Sci 83: 1312–1313.
   Web of Science ®Google Scholar
• Butler T, Kariminia A, Levy M, Kaldor J (2004): Prisoners are at risk for hepatitis C transmission. Eur J Epidemiol 19: 1119–1122.
   PubMed Web of Science ®Google Scholar
• Choi J, Xu Z, Ou JH (2003): Triple decoding of hepatitis C virus RNA by programmed translational frameshifting. Mol Cell Biol 23: 1489–1497.
   PubMedGoogle Scholar
• Choi J, Lee KJ, Zheng Y, Yamaga AK, Lai MM, Ou JH (2004): Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 39: 81–89.
   PubMed Web of Science ®Google Scholar
• Crofts N, Stewart T, Hearne P, Ping XY, Breshkin AM, Locarnini SA (1995): Spread of bloodborne viruses among Australian prison entrants. BMJ 310: 285–288.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM (1998): Hepatitis C. Lancet 351: 351–355.
   PubMed Web of Science ®Google Scholar
• Donadel E, Pontisso P, Ruvoletto MG, Gerotto M, De Salvo G, Chemello L, Casarin C, Alberti A (1998): Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response. J Med Virol 54: 7–11.
   PubMedGoogle Scholar
• Feinman SV, Berris B, Bojarski S (1988): Posttransfusion hepatitis in Toronto, Canada. Gastroenterology 95: 464–469.
   PubMed Web of Science ®Google Scholar
• Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP (2000): A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 32: 647–653.
   PubMed Web of Science ®Google Scholar
• Huang SP, Shieh GJ, Lee L, Teng HJ, Kao ST, Lin JG (1997): Inhibition effect of shengma-gegen-tang on measles virus in Vero cells and human peripheral blood mononuclear cells. Am J Chin Med 25: 89–96.
   PubMed Web of Science ®Google Scholar
• Huang SPSG, Lu HC, Lin JG, Chen JC (2003): Effect of Xaio Chai Hu Tang in peripheral blood mononuclear cells of HCV patients in Taiwan. The National Union of Chinese Medical Associations (ROC) 2: 80–92.
   Google Scholar
• Hwang DR, Tsai YC, Lee JC, Huang KK, Lin RK, Ho CH, Chiou JM, Lin YT, Hsu JT, Yeh CT (2004): Inhibition of hepatitis C virus replication by arsenic trioxide. Antimicrob Agents Chemother 48: 2876–2882.
   PubMedGoogle Scholar
• Hwang DR, Wu YS, Chang CW, Lien TW, Chen WC, Tan UK, Hsu JT, Hsieh HP (2006): Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system. Bioorg Med Chem 14: 83–91.
   PubMed Web of Science ®Google Scholar
• Kim DH, Shim SB, Kim NJ, Jang IS (1999): β-Glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum. Biol Pharm Bull 22: 162–164.
   PubMed Web of Science ®Google Scholar
• Komoda Y, Shimizu M, Sonoda Y, Sato Y (1989): Ganoderic acid and its derivatives as cholesterol synthesis inhibitors. Chem Pharm Bull (Tokyo) 37: 531–533.
   PubMed Web of Science ®Google Scholar
• Lemon S, Brown E (1994): Hepatitis C virus and chronic liver disease. In: eds. Swartzand MN, Remington JS, Current Clinical Topics in Infection Disease. New York, Vol. 14, pp. 121–141.
   Google Scholar
• Li YQ, Wang SF (2006): Anti-hepatitis B activities of ganoderic acid from Ganoderma lucidum: Biotech Lett: 837–841.
   PubMedGoogle Scholar
• Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R (1999): Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110–113.
   PubMed Web of Science ®Google Scholar
• Martin J, Quiroga JA, Navas S, Pardo M, Carreno V (1999): Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells. Cytokine 11: 267–273.
   PubMedGoogle Scholar
• Mondelli MU, Manns M, Ferrari C (1988): Does the immune response play a role in the pathogenesis of chronic liver disease? Arch Pathol Lab Med 112: 489–497.
   PubMedGoogle Scholar
• Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS (1998): Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103–107.
   PubMed Web of Science ®Google Scholar
• Park EJ, Ko G, Kim J, Sohn DH (1997): Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction. Biol Pharm Bull 20: 417–420.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D (2000): Standardization of hepatitis C virus RNA quantification. Hepatology 32: 654–659.
   PubMed Web of Science ®Google Scholar
• Purintrapiban J, Suttajit M, Forsberg N (2006): Differential activation of glucose transport in cultured muscle cells by polyphenolic compounds from Canna indica L. root. Biol Pharm Bull 29: 1995–1998.
   PubMedGoogle Scholar
• Rino Y, Tarao K, Morinaga S, Ohkawa S, Miyakawa K, Hirokawa S, Masaki T, Tarao N, Yukawa N, Saeki H, Takanashi Y, Imada T (2006): Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis. Anticancer Res 26: 2221–2226.
   PubMedGoogle Scholar
• Shields PL, Mutimer DJ, Muir D, Skidmore S, Britnell T, Roberts A, Wilde JT (2000): Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders. Br J Haematol 108: 254–258.
   PubMed Web of Science ®Google Scholar
• Shindo M, Di Bisceglie AM, Cheung L, Shih JW, Cristiano K, Feinstone SM, Hoofnagle JH (1991): Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 115: 700–704.
   PubMed Web of Science ®Google Scholar
• Simmonds P (1995): Variability of hepatitis C virus. Hepatology 21: 570–583.
   PubMed Web of Science ®Google Scholar
• Sydiskis RJ, Owen DG, Lohr JL, Rosler KH, Blomster RN (1991): Inactivation of enveloped viruses by anthraquinones extracted from plants. Antimicrob Agents Chemother 35: 2463–2466.
   PubMed Web of Science ®Google Scholar
• Szabo G, Dolganiuc A (2006): HCV immunopathogenesis: Virus-induced strategies against host immunity. Clin Liver Dis 10: 753–771.
   PubMedGoogle Scholar
• Takada N, Takase S, Enomoto N, Takada A, Date T (1992): Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 14: 35–40.
   PubMed Web of Science ®Google Scholar
• Taylor DR, Shi ST, Lai MM (2000): Hepatitis C virus and interferon resistance. Microbes Infect 2: 1743–1756.
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Hossain K, Akhand AA, Takeda K, Du J, Rifa’i M, Dai Y, Hayakawa A, Suzuki H, Nakashima I (2004): Paeoniflorin induces apoptosis of lymphocytes through a redox-linked mechanism. J Cell Biochem 93: 162–172.
   PubMed Web of Science ®Google Scholar
• Varaklioti A, Vassilaki N, Georgopoulou U, Mavromara P (2002): Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 277: 17713–17721.
   PubMed Web of Science ®Google Scholar
• Verbeeck J, Maes P, Lemey P, Pybus OG, Wollants E, Song E, Nevens F, Fevery J, Delport W, Van der Merwe S, Van Ranst M (2006): Investigating the origin and spread of hepatitis C virus genotype 5a. J Virol 80: 4220–4226.
   PubMedGoogle Scholar
• Walewski JL, Keller TR, Stump DD, Branch AD (2001): Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 7: 710–721.
   PubMedGoogle Scholar
• Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS, Shiao MS, Ho CK (1997): The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer 70: 699–705.
   PubMed Web of Science ®Google Scholar
• Wang YY, Khoo KH, Chen ST, Lin CC, Wong CH, Lin CH (2002): Studies on the immuno-modulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: Functional and proteomic analyses of a fructose-containing glycoprotein fraction responsible for the activities. Bioorg Med Chem 10: 1057–1062.
   PubMed Web of Science ®Google Scholar
• Wohnsland A, Hofmann WP, Sarrazin C (2007): Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 20: 23–38.
   PubMed Web of Science ®Google Scholar
• Wu WY, Xu Q, Shi LC, Zhang WB (2000): Inhibitory effects of Curcuma aromatica oil on proliferation of hepatoma in mice. World J Gastroenterol 6: 216–219.
   PubMed Web of Science ®Google Scholar
• Xu Z, Choi J, Yen TS, Lu W, Strohecker A, Govindarajan S, Chien D, Selby MJ, Ou J (2001): Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. Embo J 20: 3840–3848.
   PubMed Web of Science ®Google Scholar
• Yao E, Tavis JE (2005): A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J 2: 88.
   PubMed Web of Science ®Google Scholar
• Zhu M, Chang Q, Wong LK, Chong FS, Li RC (1999): Triterpene antioxidants from Ganoderma lucidum. ` 13: 529–531.
   Google Scholar